Tissue Plasminogen Activator and DNase in Empyema REPLY

Tissue Plasminogen Activator and DNase in Empyema REPLY

Bibliografske podrobnosti
Main Authors:	Rahman, N, Maskell, N, Nunn, A
Format:	Journal article
Izdano:	2011

Podobne knjige/članki

Intrapleural use of tissue plasminogen activator and DNase in pleural infection
od: Rahman, N, et al.
Izdano: (2011)

Intrapleural use of tissue plasminogen activator and DNase in pleural infection.
od: Rahman, N, et al.
Izdano: (2011)

Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: Evidence from the MIST2 randomised controlled trial.
od: Luengo-Fernandez, R, et al.
Izdano: (2019)

The biological effect of tissue plasminogen (t-PA) activator and DNase intrapleural delivery in pleural infection patients
od: Kanellakis, N, et al.
Izdano: (2018)

Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients
od: Kanellakis, N, et al.
Izdano: (2019)

The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients
od: Kanellakis, N, et al.
Izdano: (2018)

Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection
od: Benoît Bédat, et al.
Izdano: (2019-09-01)

An international survey on the use of intrapleural tissue plasminogen activator/DNase therapy for pleural infection
od: Estee P.M. Lau, et al.
Izdano: (2021-02-01)

Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients
od: Najib M Rahman, et al.
Izdano: (2019-10-01)

The authors reply
od: Rahman, N, et al.
Izdano: (2011)

Safety and Efficacy of Intrapleural Tissue Plasminogen Activator and DNase during Extended Use in Complicated Pleural Space Infections
od: Jason R. McClune, et al.
Izdano: (2016-01-01)

Bronchopleural communication following intrapleural doses of tPA/DNase for empyema
od: Bapti Roy, et al.
Izdano: (2020-10-01)

Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial
od: Michael H. Livingston, et al.
Izdano: (2017-06-01)

DNase inhibits early biofilm formation in Pseudomonas aeruginosa- or Staphylococcus aureus-induced empyema models
od: Wusheng Deng, et al.
Izdano: (2022-10-01)

A Retrospective Cohort Study Evaluating the Safety and Efficacy of Sequential versus Concurrent Intrapleural Instillation of Tissue Plasminogen Activator and DNase for Pleural Infection
od: Ken Junyang Goh, et al.
Izdano: (2023-01-01)

Precision targeting of the plasminogen activator inhibitor‐1 mechanism increases efficacy of fibrinolytic therapy in empyema
od: Galina Florova, et al.
Izdano: (2021-05-01)

Urokinase in the treatment of childhood empyema - Author's reply
od: Thomson, A, et al.
Izdano: (2003)

The neurotoxicity of tissue plasminogen activator?
od: Kaur, J, et al.
Izdano: (2004)

TISSUE PLASMINOGEN-ACTIVATOR VERSUS UROKINASE
od: Ebers, G
Izdano: (1988)

Fibrinolysis regulation by platelets retaining plasminogen and tissue-type plasminogen activator on their surface
od: T. Grinenko, et al.
Izdano: (2019-12-01)

Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
od: Yu Zuo, et al.
Izdano: (2021-01-01)

Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1
od: Lihu Gong, et al.
Izdano: (2016-03-01)

Tissue plasminogen activator in brain tissues infected with transmissible spongiform encephalopathies
od: K. Xanthopoulos, et al.
Izdano: (2005-11-01)

Intravitreal tissue plasminogen activator in submacular haemorrhage
od: Singh Preetam, et al.
Izdano: (1999-01-01)

Intravenous tissue plasminogen activator, ischemic stroke, and the risk of Kounis Syndrome
od: Nicholas G Kounis, et al.
Izdano: (2011-01-01)

Multicomponent synthesis of artificial nucleases and their RNase and DNase activity
od: Anton V. Gulevich, et al.
Izdano: (2011-08-01)

Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy
od: Nurbadriah binti Jasmiad, et al.
Izdano: (2022-09-01)

Tissue plasminogen activator and plasminogen activator inhibitor 1 contribute to sonic hedgehog-induced in vitro cerebral angiogenesis.
od: Hua Teng, et al.
Izdano: (2012-01-01)

The dependence of DNase I activity on the conformation of oligodeoxynucleotides.
od: Sutton, D, et al.
Izdano: (1997)

Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
od: Al-Hamodi, Z., et al.
Izdano: (2011)

Effect of plasminogen activator inhibitor-1 and tissue plasminogen activator polymorphisms on susceptibility to type 2 diabetes in malaysian subjects
od: Al-Hamodi, Z., et al.
Izdano: (2012)

Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
od: Saif-Ali Riyadh, et al.
Izdano: (2011-03-01)

Tissue Plasminogen Activator Is Not Involved in Methamphetamine-Induced Neurotoxicity
od: Ayumi Fukakusa, et al.
Izdano: (2008-01-01)

Role of Tissue-Type Plasminogen Activator in Ischemic Stroke
od: Yasuhiro Suzuki
Izdano: (2010-01-01)

Drug Dependence, Synaptic Plasticity, and Tissue Plasminogen Activator
od: Kiyofumi Yamada, et al.
Izdano: (2005-01-01)

Phase 1b Trial of LTI-01 (Single Chain Urokinase Plasminogen Activator, scuPA) Intrapleural Fibrinolytic Therapy (IPFT) in Patients with Complicated Parapneumonic Effusions (CPE) or Empyema
od: Idell, S, et al.
Izdano: (2019)

Management of parapneumonic effusions and empyema.
od: Psallidas, I, et al.
Izdano: (2014)

DNase-treated RNA
od: Kristie Nybo
Izdano: (2012-04-01)

Salivary Extracellular DNA and DNase Activity in Periodontitis
od: Barbora Konečná, et al.
Izdano: (2020-10-01)

Ischaemia-reperfusion injury impairs tissue plasminogen activator release in man.
od: Pedersen, C, et al.
Izdano: (2012)